CMChristian Meier

Christian Meier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christian Meier has a total of 283 co-authors. Here are the top co-authors by number of shared publications:

  • Susan S. Jick

    Boston Collaborative Drug Surveillance Program, Boston University, Boston, Massachusetts, USA

    29 shared publications
  • Marius E. Kraenzlin

    Endonet, Endocrine Clinic and Laboratory, Basel, Switzerland

    10 shared publications
  • Michael Bodmer

    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland

    8 shared publications
  • Christian Meier

    Authors' Affiliations: 1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel; 2Emergency Department, 3Division of Endocrinology, Diabetes and Clinical Nutrition, 4Hospital Pharmacy, University Hospital Basel, Basel, Switzerland; and 5Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts

    6 shared publications
  • Cornelia Schneider

    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; Hospital Pharmacy, University Hospital Basel, Basel, Switzerland

    6 shared publications
  • Yolanda B. Brauchli

    6 shared publications

Latest Publications

  • Open Access

    Adverse health outcomes across the life course in individuals with six rare bone diseases: a 10-year population-based cohort study

    by Pascal Gaechter, Christian Meier, Emanuel Christ, Fahim Ebrahimi, Alexander Kutz, Gabor Szinnai

    Background: Rare bone diseases comprise a heterogeneous group of complex and disabling conditions. Evidence on age-specific hospitalization patterns and in-hospital outcomes across multiple rare bone diseases is limited. Methods: Population-based cohort study using national hospitalization data (01/2012-12/2021). Among 11 092 151 hospitalizations, 2875 admissions of children and adults with rare bone diseases were identified via ICD-10 codes (X-linked hypophosphatemia, osteogenesis imperfecta, fibrous dysplasia, achondroplasia, pseudohypoparathyroidism, fibrodysplasia ossificans progressiva) and compared with 14 375 age-, sex-, and patient complexity–matched hospitalizations from the general population. Results: Hospitalization patterns differed substantially by disease and age. Patients with X-linked hypophosphatemia had an increased risk of emergency admissions in late adulthood, whereas planned admissions were more frequent in early adulthood among patients with achondroplasia and fibrous dysplasia. Malignancies were diagnosed in 22.7% of patients with X-linked hypophosphatemia, and fractures were the leading cause of hospitalization among patients with osteogenesis imperfecta. Across the rare bone diseases, patients had higher all-cause in-hospital mortality compared with matched controls (RR, 2.26; 95% CI, 1.77-2.89), longer hospital stays (median difference, 6 days [interquartile range [IQR] 3-13 days]), higher risk of ICU admission (RR, 3.08; 95% CI, 2.78-3.40), and higher readmission risk (RR, 1.31, 95% CI, 1.15-1.49). Conclusions: The studied rare bone diseases are associated with distinct, disease-specific hospitalization patterns and substantially worse in-hospital outcomes across the lifespan. This underscores the need for tailored preventive strategies and coordinated, long-term care models for patients with rare bone diseases.

  • Open Access

    Sex- and site-specific reference data for size-invariant properties using multi-stack HRpQCT

    by Simone Poncioni, Dominique Lüscher, Michael Indermaur, Daniela A Frauchiger, Christian Meier, Philippe Zysset, Kurt Lippuner

    HRpQCT is emerging as a promising evolution to DXA for longitudinal assessment of bone properties and strength estimation beyond FN aBMD, as it provides a detailed 3D representation and separate quantification of trabecular and cortical compartments. Reference data exist for thin single stacks of 10.2 mm in second-generation HRpQCT, but these sections may not fully capture clinically relevant fracture locations and pose challenges for longitudinal monitoring due to their limited thickness. Reported parameters are mainly size-dependent properties susceptible to bias from skeletal dimensions, potentially concealing changes in bone quality at the material level. Moreover, microstructural parameters are derived from densitometric information, making them partially redundant. This study provides the first age-, sex-, and site-specific reference data for a novel multi-stack on second-generation HRpQCT at the distal radius and tibia in 381 healthy participants (144F, 237M) from a primarily Caucasian population aged 20-92 yr and identifies the size-independent parameters most sensitive to age for improved bone health assessment. Six size-independent parameters relevant for estimated mechanical properties or exhibiting short trend assessment intervals were selected as candidates for improved bone health assessment: 2 densitometric properties (total volumetric BMD, cortical volumetric BMD), 1 size-independent geometrical property (relative cortical thickness), 2 microstructural properties (trabecular degree of anisotropy, trabecular bone volume over total volume), and 1 mechanical property (apparent yield stress [appσy]) estimated by homogenized finite elements. Intensive mechanical properties provided more sensitive follow-up estimations. Cortical volumetric BMD, especially in the weight-bearing tibia in women, was the most sensitive with age. Matched comparisons with single-stack counterparts demonstrated good agreement between densitometric and microstructural properties, supporting potential cross-study and cross-protocol comparisons. The present work proposes an alternative set of size-independent variables for multi-stack HRpQCT, which may offer a refined assessment of bone health and longitudinal monitoring.

  • Open Access

    Response to the comments on normalization of hyponatremia in hospitalized patients decreases osteoclast activity

    by Laura Potasso, Julie Refardt, Sophie Monnerat, Christian Meier, Mirjam Christ-Crain

    We thank Xueguang Lin and Qi Sun as well as Wei Lu, Chenchen Zhang, and Hanning Zhang for their thoughtful feedback, including their recognition of the potential clinical implications of our paper,1 for suggesting possible underlying pathophysiological mechanisms that may explain our findings, and for highlighting possible implications and future perspectives offered by our analysis. There are a couple of points we would like to address.

  • Open Access

    Normalization of hyponatremia in hospitalized patients decreases osteoclast activity

    by Laura Potasso, Julie Refardt, Sophie Monnerat, Christian Meier, Mirjam Christ-Crain

    Objective: Hyponatremia, the most common electrolyte disorder in hospitalized patients, has been largely associated with increased risk of osteoporosis. Preclinical studies suggest that hyponatremia stimulates osteoclast activity. This study evaluated whether normalization of hyponatremia impacts osteoclast activity. Design: In this prospective, observational study we included patients with serum sodium .05). Conclusions: In hospitalized patients with hyponatremia, sodium normalization is associated with attenuated osteoclast activity. Correction of even mild hyponatremia could thus be beneficial for counteracting bone loss.


  • Bone microstructure and TBS in diabetes: what have we learned? A narrative review

    by S. Ferrari, K. E. Akesson, N. Al-Daghri, E. Biver, M. Chandran, T. Chevalley, R. G. Josse, D. L. Kendler, N. E. Lane, P. Makras, et al.

    Diabetes is associated with an increased risk of fracture. Areal bone mineral density (aBMD), the most reliable indicator of fracture risk in healthy adult


  • Open Access

    Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus

    by Cyril Traechslin, Lilian Sewing, Sandra Baumann, Leticia Grize, Janina Vavanikunnel, Marius Kraenzlin, Christoph Henzen, Christian Meier


  • Open Access

    Correction to: Serum Pentosidine in Relation to Obesity in Patients with Type 2 Diabetes and Healthy Controls

    by Sandra Baumann, Lilian Sewing, Cyril Traechslin, Wilma Verhagen-Kamerbeek, Leticia Grize, Marius Kraenzlin, Christian Meier

  • [Osteoporosis therapy - Update 2025, Part 2: Sequential osteoporosis therapy].

    by Christian Meier, Judith Everts-Graber, Serge Ferrari

    Osteoporosis is a chronic disease that requires lifelong therapy management that includes both non-drug and drug-based approaches. The availability of various drugs for osteoporosis therapy, characterized by different mechanisms of action, has significantly changed treatment strategies in recent years. Due to the potential treatment risks associated with long-term monotherapy and the fact that the osteoanabolic therapies used in patients with a high fracture risk are time-limited, sequential treatment strategies are increasingly being used today. The aim of this review article is to present the significance of different treatment sequences in osteoporosis drug therapy.


  • [Osteoporosis therapy - Update 2025, Part 1: Antiresorptive and osteoanabolic therapy options].

    by Serge Ferrari, Judith Everts-Graber, Christian Meier

    Osteoporosis is a chronic disease that requires lifelong therapy management that includes both preventive measures and pharmacological approaches. The medical treatment of osteoporosis has changed considerably in recent years, particularly due to the availability of new substances, especially osteoanabolic drugs. The wide range of antiresorptive (estrogens, raloxifene, bisphosphonates, denosumab) and osteoanabolic (teriparatide, romosozumab) preparations for the treatment of osteoporosis makes it possible today to use them in a targeted manner based on the individual fracture risk. The uncertainty in their use can contribute to the underuse and lack of treatment of patients with osteoporosis, especially patients with a high fracture risk. This review article will summarize the mechanisms of action and clinical efficacy of antiresorptive and, in particular, anabolic agents and discuss its value for osteoporosis therapy.


  • [Introduction: Osteoporosis].

    by Christian Meier